NanoViricides, Inc. (NNVC)
NNVC Stock Price Chart
Explore NanoViricides, Inc. interactive price chart. Choose custom timeframes to analyze NNVC price movements and trends.
NNVC Company Profile
Discover essential business fundamentals and corporate details for NanoViricides, Inc. (NNVC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Oct 2005
Employees
7.00
Website
https://www.nanoviricides.comCEO
Anil R. Diwan
Description
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NNVC Financial Timeline
Browse a chronological timeline of NanoViricides, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 26 Sept 2025
Earnings released on 15 May 2025
EPS came in at -$0.14 surpassing the estimated -$0.19 by +26.32%.
Earnings released on 14 Feb 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 14 Nov 2024
EPS came in at -$0.23 falling short of the estimated -$0.17 by -35.29%.
Earnings released on 27 Sept 2024
EPS came in at -$0.19 surpassing the estimated -$0.20 by +5.00%.
Earnings released on 15 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%.
Earnings released on 14 Feb 2024
EPS came in at -$0.18 surpassing the estimated -$0.19 by +5.26%.
Earnings released on 14 Nov 2023
EPS came in at -$0.17 matching the estimated -$0.17.
Earnings released on 13 Oct 2023
EPS came in at -$0.31 falling short of the estimated -$0.17 by -82.35%.
Earnings released on 15 May 2023
EPS came in at -$0.15 surpassing the estimated -$0.17 by +11.76%.
Earnings released on 14 Feb 2023
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%.
Earnings released on 14 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%.
Earnings released on 13 Oct 2022
EPS came in at -$0.15 surpassing the estimated -$0.23 by +34.78%.
Earnings released on 17 May 2022
EPS came in at -$0.16 matching the estimated -$0.16.
Earnings released on 14 Feb 2022
EPS came in at -$0.17 surpassing the estimated -$0.22 by +22.73%.
Earnings released on 15 Nov 2021
EPS came in at -$0.23 falling short of the estimated -$0.20 by -15.00%.
Earnings released on 12 Oct 2021
EPS came in at -$0.18 .
Earnings released on 14 May 2021
EPS came in at -$0.19 .
Earnings released on 16 Feb 2021
EPS came in at -$0.22 .
Earnings released on 16 Nov 2020
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%.
Earnings released on 13 Oct 2020
EPS came in at -$0.18 .
NNVC Stock Performance
Access detailed NNVC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.